[Skip to Navigation]
Sign In
Comment & Response
September 12, 2019

Lack of Robust Prognostic Biomarkers for Immunotherapy in Breast Cancer—Adverse Events—In Reply

Author Affiliations
  • 1Perlmutter Cancer Center, NYU School of Medicine, New York, New York
  • 2Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3Breast Oncology Program, Dana-Farber Cancer Institute, Brigham and Women’s Cancer Center, Boston, Massachusetts
JAMA Oncol. 2019;5(11):1640. doi:10.1001/jamaoncol.2019.3605

In Reply We appreciate the letter by Yang and the opportunity to comment on the safety of immune checkpoint blockade (ICB) in breast cancer. This important subject was not addressed extensively in our original article due to space limitations.1 However, since that publication, a comprehensive review by D’Abreo and Adams2 on the incidence of adverse events (AEs) with particular emphasis on immune-related adverse events (irAEs) in patients with breast cancer has been published. That review describes more than 1000 patients with triple-negative breast cancer included in published clinical trials of ICB alone or in combination with chemotherapy. The most common organ-specific irAEs were pruritus or rash occurring in 18% of patients, followed by hypothyroidism in 12%, and hepatitis or elevated transaminases in 10%. Less frequent events with an incidence greater than 1% were hyperthyroidism (5%), autoimmune hematologic abnormalities (4%), pneumonitis (3%), and diarrhea or colitis (2.5%). Grade 3 or higher irAEs were observed in 7% of patients with breast cancer.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words